All In Biotech

NDA 204569 · Merck Sharp Dohme

Belsomra

Suvorexant · Oral · Orexin Receptor Antagonist

Novel

Last checked: Nov 19, 2026Latest source record: Mar 10, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2014

Aug 13, 2014

Approved uses

2

Original approval plus efficacy supplements

Registered trials

69

7 Phase 3, 11 recruiting

FAERS reports

13,031

4,515 serious, 718 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Mar 10, 2025.

BELSOMRA ® (suvorexant) is indicated for the treatment of insomnia characterized by difficulties with sleep onset and/or sleep maintenance. BELSOMRA is an orexin receptor antagonist indicated for the treatment of insomnia, characterized by difficulties with sleep onset and/or sleep maintenance ( 1 ).

Mechanism: The mechanism of action of suvorexant in the treatment of insomnia is presumed to be through antagonism of orexin receptors. The orexin neuropeptide signaling system plays a role in wakefulness. Blocking the binding of wake-promoting neuropeptides orexin A and orexin B to receptors OX1R and OX2R is thought to suppress wake drive.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

4 products under this application
  • BELSOMRA · SUVOREXANT 20MG · TABLET, ORAL · Prescription
  • BELSOMRA · SUVOREXANT 10MG · TABLET, ORAL · Prescription
  • BELSOMRA · SUVOREXANT 15MG · TABLET, ORAL · Prescription
  • BELSOMRA · SUVOREXANT 5MG · TABLET, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Suvorexant" as an intervention, any sponsor and status, largest first.

All 69 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective3,050
  • nightmare743
  • somnolence738
  • insomnia688
  • abnormal dreams603
  • headache549
  • feeling abnormal489
  • nausea395
  • no adverse event389
  • hallucination380
  • fatigue365
  • dizziness341

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
201413
20152,481
20162,499
20172,016
20181,159
2019926
2020783
2021714
2022600
2023602
2024492
2025417
2026329

Recalls

2 FDA enforcement reports for this application.

  • Jul 21, 2025 · Class II · Ongoing

    Failed Dissolution Specifications: potential for delayed dissolution of the dose after administration which may result in delayed release of the drug, delaying onset of sleep.

  • Mar 15, 2021 · Class II · Terminated

    CGMP Deviations: Intermittent exposure to temperature excursion during storage.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Belsomra (Suvorexant)

2024 spending

$150M

Beneficiaries

77,098

315,401 claims

Per beneficiary

$1,948

$14.51 per unit

View as table
YearSpending
2020$104,140,127
2021$114,695,562
2022$130,017,868
2023$161,202,978
2024$150,180,015

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 105 on PubMed

Sponsor: Merck & Co.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.